Scholarlink

<p>Breast cancer (BC) is among the most prevalent and immunogenic malignancies in women, characterized by rapid proliferation and significant immune cell infiltration into the tumor microenvironment (TME). The programmed cell death protein 1 (PD-1) and its ligand PD-L1 form a critical immune checkpoint axis exploited by tumors to evade immune detection. Targeting this pathway with immune checkpoint inhibitors (ICIs) has shown clinical promise, particularly in triple-negative breast cancer (TNBC). The IMpassion130 trial demonstrated that atezolizumab plus nab-paclitaxel extended progression-free survival (PFS) to 7.5&#xa0;months compared to 5.0&#xa0;months with chemotherapy alone. Similarly, the KEYNOTE-522 trial reported a 64.8% pathological complete response (pCR) rate with pembrolizumab-chemotherapy versus 51.2% in the control group. This review summarizes the PD-1/PD-L1 pathway and highlights the therapeutic impact, clinical advances, and future potential of ICIs in BC treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immune checkpoint inhibition in breast cancer: targeting PD-1/PD-L1 pathway for therapeutic advances

  • 期刊论文

  • 发表日期：

    2025年10月22日

查看全文
  • Yunjin Shin,
  • Kibeom Shin,
  • Sihyeon Lee,
  • Yena Son,
  • Inmoo Rhee

摘要

Breast cancer (BC) is among the most prevalent and immunogenic malignancies in women, characterized by rapid proliferation and significant immune cell infiltration into the tumor microenvironment (TME). The programmed cell death protein 1 (PD-1) and its ligand PD-L1 form a critical immune checkpoint axis exploited by tumors to evade immune detection. Targeting this pathway with immune checkpoint inhibitors (ICIs) has shown clinical promise, particularly in triple-negative breast cancer (TNBC). The IMpassion130 trial demonstrated that atezolizumab plus nab-paclitaxel extended progression-free survival (PFS) to 7.5 months compared to 5.0 months with chemotherapy alone. Similarly, the KEYNOTE-522 trial reported a 64.8% pathological complete response (pCR) rate with pembrolizumab-chemotherapy versus 51.2% in the control group. This review summarizes the PD-1/PD-L1 pathway and highlights the therapeutic impact, clinical advances, and future potential of ICIs in BC treatment.